×

Bullish on Biotechs

2:34 PM ET Wed, 4 April 2012

Keryx Biopharma is down more than 70 percent after one of its colon cancer drugs failed a late stage clinical trial, with Mark Tepper, Strategic Wealth Partners managing partner.